SOHO 2018 | Updates on the survival rates of MLL treatments
Mixed lineage leukemia (MLL) rearranged acute myeloid leukemia (AML) is a severely aggressive disease which puts patients, especially children, at high risk. Speaking at the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, Rob Pieters, MD, PhD, of Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands, discusses the current chemotherapy and corresponding survival rates in the treatments for MLL rearranged ALL. He also highlights his team’s randomized trial of the effect of drugs such as FLT3 inhibitors and nucleoside analogues such as araC in young infants (NCT00015873).
Get great new content delivered to your inboxSign up